tiprankstipranks
Advertisement
Advertisement

INKT Stock Latest News

MiNK Therapeutics: Buy Rating on Emerging Pulmonary Franchise and Key agenT-797 ARDS Catalyst
RatingsMiNK Therapeutics: Buy Rating on Emerging Pulmonary Franchise and Key agenT-797 ARDS Catalyst
9d ago
INKT
MiNK Therapeutics’ Earnings Call Signals High-Risk Upside
PremiumCompany Announcements
MiNK Therapeutics’ Earnings Call Signals High-Risk Upside
9d ago
INKT
INKT Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
INKT Upcoming Earnings Report: What to Expect?
12d ago
INKT
MiNK Therapeutics Explores Strategic Partnerships and Trial Collaborations
PremiumCompany Announcements
MiNK Therapeutics Explores Strategic Partnerships and Trial Collaborations
14d ago
8K
INKT
MiNK Therapeutics Appoints New Principal Financial and Accounting Officers
PremiumCompany Announcements
MiNK Therapeutics Appoints New Principal Financial and Accounting Officers
21d ago
8K
INKT
3 Penny Stocks to Watch Now, 3/11/26
PremiumMarket News3 Penny Stocks to Watch Now, 3/11/26
30d ago
ATPC
INKT
Morning News Wrap-Up 3/10/26: Tuesday’s Biggest Stock Market Stories!
Premium
Market News
Morning News Wrap-Up 3/10/26: Tuesday’s Biggest Stock Market Stories!
1M ago
GD
AMD
MiNK Therapeutics: Buy Rating Backed by Non-Dilutive PRAME iNKT Partnership and Expanded Oncology Upside
Premium
Ratings
MiNK Therapeutics: Buy Rating Backed by Non-Dilutive PRAME iNKT Partnership and Expanded Oncology Upside
1M ago
INKT
Why Is MiNK Therapeutics Stock (INKT) Up Today?
PremiumMarket News
Why Is MiNK Therapeutics Stock (INKT) Up Today?
1M ago
INKT
MiNK Therapeutics announces strategic collaboration with C-Further
PremiumThe Fly
MiNK Therapeutics announces strategic collaboration with C-Further
1M ago
INKT
MiNK Therapeutics announces new invariant natural killer T cells data
PremiumThe Fly
MiNK Therapeutics announces new invariant natural killer T cells data
2M ago
INKT
MiNK, University of Wisconsin-Madison announce Phase 1 agenT-797 trial
PremiumThe Fly
MiNK, University of Wisconsin-Madison announce Phase 1 agenT-797 trial
3M ago
INKT
MiNK Therapeutics announces board resignation amid public appointment
PremiumCompany AnnouncementsMiNK Therapeutics announces board resignation amid public appointment
3M ago
8K
INKT
MiNK Therapeutics announces publication of new preclinical data for MiNK-215
Premium
The Fly
MiNK Therapeutics announces publication of new preclinical data for MiNK-215
5M ago
INKT
MiNK Therapeutics Advances iNKT Platform in Q3 2025
Premium
Company Announcements
MiNK Therapeutics Advances iNKT Platform in Q3 2025
5M ago
INKT
MiNK Therapeutics Earnings Call: Positive Sentiment and Promising Future
PremiumCompany Announcements
MiNK Therapeutics Earnings Call: Positive Sentiment and Promising Future
5M ago
INKT
MiNK Therapeutics: Advancing Clinical Trials and Strategic Partnerships to Address GvHD and Pulmonary Diseases
PremiumRatings
MiNK Therapeutics: Advancing Clinical Trials and Strategic Partnerships to Address GvHD and Pulmonary Diseases
5M ago
INKT
MiNK Therapeutics reports Q3 EPS (65c) vs (46c) last year
PremiumThe Fly
MiNK Therapeutics reports Q3 EPS (65c) vs (46c) last year
5M ago
INKT
INKT Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
INKT Upcoming Earnings Report: What to Expect?
5M ago
INKT
MiNK Therapeutics files $150M mixed securities shelf
PremiumThe FlyMiNK Therapeutics files $150M mixed securities shelf
5M ago
INKT
Promising Phase 1 Results for MiNK Therapeutics’ agenT-797 Support Buy Rating
Premium
Ratings
Promising Phase 1 Results for MiNK Therapeutics’ agenT-797 Support Buy Rating
5M ago
INKT
MiNK Therapeutics reports updated clinical results on agenT-797
Premium
The Fly
MiNK Therapeutics reports updated clinical results on agenT-797
5M ago
INKT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >